CT102 is an antisense nucleic acid drug targeting the IGF1R gene involved in liver cancer. The drug was jointly developed by WANG Shengqi, a researcher at the Academy of Military Sciences, and Hangzhou Tianlong Pharmaceutical Co. China is a country with a high incidence of liver cancer. The number of people who die from this disease each year is as much as 380,000, accounting for more than half of the world’s total.
China Bio news release, April 19, 2018
CFDA approves China’s first antisense drug